

Curriculum Vitae



نام	حنیفه میرطاووسی مهیاری
زبان	فارسی و انگلیسی (تسلط کامل)
آدرس محل کار	الهیه، خیابان گلنار، ساختمان گالریا رزیدنس، طبقه اول، واحد ۱۰۲، مرکز خدمات تخصصی ژنتیک حنیفا بیمارستان مسیح دانشوری، مرکز تحقیقات پیوند ریه
ایمیل	hanifehmirmah@yahoo.com
h-index	۹
RGscore	۱۹/۳۴

Education

- بهمن ۱۳۹۲ - شهریور ۱۳۹۸: دکترای تخصصی ژنتیک پزشکی، دانشگاه علوم پزشکی تهران.
- بهمن ۱۳۷۹ - اردیبهشت ۱۳۸۷: پزشکی عمومی، دانشگاه علوم پزشکی شهید بهشتی تهران.

University Entrance Exam Ranking

- رتبه ۱۶۷ آزمون سراسری
- رتبه ۱ آزمون دکترای تخصصی ژنتیک پزشکی

Scientific Associations

- انجمن ژنتیک انسانی آمریکا
- انجمن ژنتیک ایران
- انجمن علمی ژنتیک پزشکی ایران
- انجمن ژنتیک پزشکی ایران

Publications

- 1. Primary Erlotinib Resistance in a Patient with Non-Small Cell Lung Cancer Carrying Simultaneous Compound EGFR L718A, Q849H, and L858R Mutations**
Mirtavoos-mahyari, Hanifeh, Rismani, Elham, Lotfabadi, Alireza Sarkar, Dezfouli, Azizollah Abbasi, Sheikhy, Kambiz, Dezfouli, Mojtaba Mokhber and Heshmatnia, Jalal
Biomolecular Concepts, vol. 12, no. 1, 2021, pp. 164-174. <https://doi.org/10.1515/bmc-2021-0018>
Impact Factor:3.3
- 2. TGF- β in radiotherapy: Mechanisms of tumor resistance and normal tissues injury**
Bagher Farhood, Ehsan khodamoradi, Mojtaba Hoseini-Ghahfarokhi, Elahe Motevaseli, **Hanifeh Mirtavoos-Mahyari**, Ahmed Elejo Musa, Masoud Najafi, Pharmacological Research, Volume 155,2020,104745,ISSN 1043-6618, <https://doi.org/10.1016/j.phrs.2020.104745>.
Impact Factor:3.78
- 3. Clinical population genetic analysis of variants in the SARS-CoV-2 receptor ACE2**
Ardehshirdavani, Amin & Zakeri, Pooya & Mehrtash, Amirhosein & Hosseini, Sayed & Li, Guangdi & **Mirtavoos-Mahyari, Hanifeh** & Soltanpour, Mohamad & Tavallaie, Mahmoud & Moreau, Yves. (2020). 10.1101/2020.05.27.20115071.
- 4. Circulating free DNA concentration as a marker of disease recurrence and metastatic potential in lung cancer**
Mirtavoos-Mahyari, Hanifeh & Ghafouri-Fard, Soudeh & Khosravi, Adnan & Motevaseli, Elaheh & Esfahani-Monfared, Zahra & Seifi, Sharareh & Kholghi Oskooei, Vahid & Modarressi, Mohammad H. (2019). 8. 10.1186/s40169-019-0229-6.
Impact Factor:1.00
- 5. Boosting immune system against cancer by melatonin: A mechanistic viewpoint.**
Mortezaee K, Potes Y, **Mirtavoos-Mahyari H**, Motevaseli E, Shabeeb D, Musa AE, Najafi M, Farhood B. Life Sci. 2019 Oct 17;238:116960. doi: 10.1016/j.lfs.2019.116960.
Impact Factor:3.234
- 6. Identification of common vaginal Lactobacilli immunoreactive proteins by immunoproteomic techniques.** Tooli LF, Shirzad M, Modarressi MH, **Mirtavoos-Mahyari H**, Amoozegar MA, Hantoushzadeh S, Motevaseli E. World J Microbiol Biotechnol. 2019 Oct 13;35(10):161. doi: 10.1007/s11274-019-2736-4
Impact Factor:2.62
- 7. Targets for improving tumor response to radiotherapy.**
Mortezaee K, Parwaie W, Motevaseli E, **Mirtavoos-Mahyari H**, Musa AE, Shabeeb D, Esmaily F, Najafi M, Farhood B.

Int Immunopharmacol. 2019 Nov;76:105847. doi: 10.1016/j.intimp.2019.105847. Epub 2019 Aug 26. Review

Impact Factor:3.1

8. **Selenium as an adjuvant for modification of radiation response.**
Farhood B, Mortezaee K, Motevaseli E, **Mirtavoos-Mahyari H**, Shabeeb D, Eleojo Musa A, Sanikhani NS, Najafi M, Ahmadi A.
J Cell Biochem. 2019 Nov;120(11):18559-18571. doi: 10.1002/jcb.29171. Epub 2019 Jun 12
Impact Factor:3.1
9. **Effects of Coffee, Black Tea and Green Tea Consumption on the Risk of Non-Hodgkin's Lymphoma: A Systematic Review and Dose-Response Meta-Analysis of Observational Studies.**
Mirtavoos-Mahyari H, Salehipour P, Parohan M, Sadeghi A.
Nutr Cancer. 2019;71(6):887-897. doi: 10.1080/01635581.2019.1595055. Epub 2019 May 2
Impact Factor:2.09
10. **Circulating free DNA concentration as a marker of disease recurrence and metastatic potential in lung cancer**
Mirtavoos-Mahyari H, Ghafouri-Fard S, Khosravi A, Motevaseli E, Esfahani-Monfared Z, Seifi S, Salimi B, Oskooei VK, Ghadami M, Modarressi MH.
Clin Transl Med. 2019 Apr 18;8(1):14. doi: 10.1186/s40169-019-0229-6
Impact Factor:2.4
11. **Long non-coding RNAs: Diverse roles in various disorders.** Azizi Z, **Mirtavoos-Mahyari H**, Karimi R, Noroozi Z, Motevaseli E.
Hum Antibodies. 2019 Mar 15. doi: 10.3233/HAB-190374.
Impact Factor:1.2
12. **Mechanisms of apoptosis modulation by curcumin: Implications for cancer therapy** Mortezaee K, Salehi E, **Mirtavoos-Mahyari H**, Motevaseli E, Najafi M, Farhood B, Rosengren RJ, Sahebkar A.
J Cell Physiol. 2019 Aug;234(8):12537-12550. doi: 10.1002/jcp.28122. Epub 2019 Jan 8. Review
Impact Factor:3.9
13. **-A Phase IV Efficacy Study of Formeta Plus Carboplatin as First-Line Treatment of Advanced Non-Squamous, Non-Small Cell Lung Cancer in Iran: An Affordable Price with Clinical Benefit**
Khosravi A, Salimi B, Esfahani-Monfared Z, Seifi S, **Mirtavoos-Mahyari H**.
Asian Pac J Cancer Prev. 2018 Oct 26;19(10):2973-2978
14. **Melatonin as an adjuvant in radiotherapy for radioprotection and radio sensitization**
Farhood B, Goradel NH, Mortezaee K, Khanlarkhani N, Salehi E, Nashtaei MS, **Mirtavoos-Mahyari H**, Motevaseli E, Shabeeb D, Musa AE, Najafi M.
Clin Transl Oncol. 2019 Mar;21(3):268-279. doi: 10.1007/s12094-018-1934-0. Epub 2018 Aug 22. Review
Impact Factor:2.4

15. **Overexpression of HER2/neu as a Prognostic Value in Iranian Women with Early-Stage Breast Cancer; A Single Institute Study.**
Mirtavoos Mahyari H, Khosravi A, Mirtavoos Mahyari Z, Esfahani Monfared Z, Khosravi N.
Iran Red Crescent Med J. 2014 Nov 11;16(11):e16005. doi: 10.5812/ircmj.16005. eCollection 2014 Nov
16. **Mechanisms for Radioprotection by Melatonin; Can it be Used as a Radiation Countermeasure?**
Amini P, **Mirtavoos-Mahyari H**, Motevaseli E, Shabeeb D, Musa AE, Cheki M, Farhood B, Yahyapour R, Shirazi A, Goushbolagh NA, Najafi M.
Curr Mol Pharmacol. 2019;12(1):2-11. doi: 10.2174/1874467211666180802164449. Review
Impact Factor:3.87
17. **Cell Free Tumoral DNA Versus Paraffin Block Epidermal Growth Factor Receptor Mutation Detection in Patients with Non-Small Cell Lung Cancer**
Mirtavoos-Mahyari H, Khosravi A, Motevaseli E, Esfahani-Monfared Z, Seifi S, Salimi B, Oskooei VK, Ghadami M, Modarressi MH.(2019)
APJCP. 20. 3591-3596. 10.31557/APJCP.2019.20.12.3591.
Impact Factor:0.5
18. **Clinical outcome of Hodgkin lymphoma: A single center study**
Sharareh Seifi, Adnan Khosravi, Zahra Esfahani-Monfared, Babak Salimi, **Hanifeh Mirtavoos-Mahyari**
DOI: 10.1200/JCO.2018.36.15_suppl.e19515 *Journal of Clinical Oncology* 36, no. 15_suppl
Published online (ASCO) June 01, 2018.
19. **Human epidermal growth factor receptor 2 and estrogen receptor status in respect to tumor characteristics in non-metastatic breast cancer**
Mirtavoos-Mahyari H, Khosravi A, Esfahani-Monfared Z.
Tanaffos. 2014;13(1):26-34
20. **Two thymus-related autoimmune disorders: a case report and review of the literature**
Mirtavoos-Mahyari H, Khosravi A, Esfahani-Monfared Z, Shadmehr MB.
Onco Targets Ther. 2014 May 10;7:633-6. doi: 10.2147/OTT.S58194. eCollection 2014
Impact Factor:3.04

Preprint Articles

- 21. An Inherited Cancer Syndrome Due to a Germline Monoallelic EGFR Mutation with Loss of Heterozygosity in Lung and Breast Tumors**
Mirtavoos-Mahyari, H.; Bahreini, F.; Vahidnezhad, H.
Preprints 2021, 2021090492 (doi: 10.20944/preprints202109.0492.v1).
- 22. Clinical Whole-Exome Sequencing Analysis Reveals a Novel Missense COL11A1 Mutation Resulting in an 18-Week Iranian Male Aborted Fetus with Fibrochondrogenesis 1: A Case Report**
Mirtavoos-Mahyari, Hanifeh & Ajami, Sanaz & Mehrtash, Amirhosein & Marashiyan, Mahya & Bahreini, Farbod & Sheikhy, Kambiz & Ghanbari, Sogol & Ardeshirdavani, Amin. (2021). 10.21203/rs.3.rs-369154/v1.

Articles under Revision

- 23. Increased expression of long noncoding RNA SPRY4-IT1 in breast tissue is associated with breast cancer risk factors in healthy women**
Yaser Mansoor, Abdolreza Daraei; Zahra Zendeabad; Javad Tavakkoly-Bazzaz; Mohammad Mehdi Naghizadeh; Ziba Nariman-Saleh-Fam; Milad Bastami; Sohrab Najafipour; Hosein Mansoori; Amin Yousefvand; **Hanifeh Mirtavoos-Mahyari**; Farzaneh Darbeheshti; Negar Mousavi
Journal: Current Research in Translational Medicine
- 24. EGFR Mutations and Responses to EGFR Tyrosine Kinase Inhibitors in a Large Cohort of Iranian Patients with Non-small-cell Lung Cancer (NSCLC)**
Mirtavoos-Mahyari H, Khosravi A, Esfahani-Monfared Z, Ghadami M, Modarressi MH. Journal: Lung Cancer

Ongoing projects

25. Diagnosis of EGFR common mutations using CRISPER technology
26. Effects of ERCC1 gene in non-small cell lung cancer in Masih Daneshvari Hospita
27. Investigation of effects of HER2 gene in stomach cancer in Masih Daneshvari Hospita
28. Investigation of palliative care of Docetaxel vs Gemcitabine vs Best Supportive Care in PFS of NSCLC patients in Masih Daneshvari Hospital
29. Palliative chemotherapy with Irinotecan in NSCLC patients in Masih Daneshvari Hospital

30. Prevalence of hearing loss in patients harboring Cisplatin chemotherapy in Masih Daneshvari Hospital

Farsi Publications

۳۱- مروری بر کاربرد DNA در گردش تومور در بررسی جهش های ژن گیرنده رشد اپیتلیالی سرطان ریه

۳۲- تفاوت نگرش و آگاهی بیماران با خانواده ایشان در خصوص سرطان و مراحل انتهایی آن

۳۳- اپی ژنتیک و سرطان ریه

(All published in Nafas journal. (Shahid Beheshti University of Medical Science)

International Poster and Oral Presentations

1. **Human epidermal growth factor receptor 2 and estrogen receptor status in respect to tumor characteristics in non-metastatic breast cancer.** Poster presentation in **ICACT 2013** in Paris (European Society of Medical Oncology)
 - a. **Mirtavoos-Mahyari H**, Khosravi A, Esfahani-Monfared Z.
2. **Does overexpression of HER2/neu have a Prognostic Value in Iranian Women with Early-Stage Breast Cancer?** Poster presentation in **ICACT 2014** in Paris (European Society of Medical Oncology)
 - a. **Mirtavoos Mahyari H**, Khosravi A, Mirtavoos Mahyari Z, Esfahani Monfared Z
3. **Two thymus-related autoimmune disorders: a case report and review of the literature.** Poster presentation in **ICACT 2015** in Paris:(European Society of Medical Oncology)
 - a. **Mirtavoos-Mahyari H**, Khosravi A, Esfahani-Monfared Z, Shadmehr MB.
4. **Novel and Recurrent FERMT1 Mutations in Iranian Families with the Kindler Syndrome.** Poster presentation in **ASHG 2014** (American Society of Human Genetics)
 - a. L Youssefian, H Vahidnezhad, M Barzegar, Q Li, S Sotoudeh, A Yazdanfar, AM Kajbafzadeh, **H Mirtavoos Mahyari**, AH Ehsani, F Agha-Hosseini, S Zeinali, M Tabrizi, J Uitto
5. **Personalized Medicine and Epidermal Growth Factor Receptor Mutations in Non-Small Cell lung Cancer.** Oral presentation (in English) in second International Conference of Personalized Medicine in IRAN
 - a. **Hanifeh Mirtavoosi Mahyari**

6. Clinical outcome of Hodgkin lymphoma: A single center study

Poster presentation in American Society of Clinical Oncology (ASCO)2018.

Sharareh Seifi, Adnan Khosravi, Zahra Esfahani-Monfared, Babak Salimi, Hanifeh Mirtavoos-Mahyari

Conferences and Training Courses

1. Attended in ESHG 2016 (European Society of Human Genetics)
2. Attended in 1-year NGS data analysis classes in genome fan Institute. (July2017-July2018)
3. Attended in Homology protein and Docking Courses in genome fan Institute and Pasteur Institute. (Sep 2018-march 2019)
4. Attended in Bioinformatic course conducted by TUMS (Sep2017-Nov2017)
5. Attended in International anti-Cancer Treatment (ICACT 2013) conducted by European Society of Clinical Oncology (ESMO), (Nov2013)
6. Attended in International anti-Cancer Treatment (ICACT 2014) conducted by European Society of Clinical Oncology (ESMO), (Nov2014)
7. Attended in International anti-Cancer Treatment (ICACT 2015) conducted by European Society of Clinical Oncology (ESMO), (Nov2015)
8. Attended in workshop on “How to Publish a Scientific Article “in TUMS, (Nov2016)
9. Attended in International Congress of Biomedicine (ICB) in IRAN. (Dec 2017)
10. Attended in Second Congress of Personalized Medicine in IRAN. (Jan 2018)
11. Attended in “Skin Care” workshop in SBUMS. (Nov 2013)
12. Attended in Workshop on “Linux” (July 2017-Nov 2017)
13. Attended in several workshops about “Writing a Scientific Paper” in TUMS
14. Attended in several webinars on “Cell Free Tumoral DNA “
15. Attended in several webinars on “Cancer Treatment”
16. On- the-job training about cancer treatment (Jan 2009-now)

17. On- the-job training about Beauty Skin Care in private office (Jan 2010-March 2013)

Experience in Teaching and clinic

1. Teaching “Protein Bioinformatics and Databases” to MSC and PhD students of Medical Genetics in TUMS.(Feb 2019-Now)
2. Teaching “Genetic Engineering” to MSC and PhD students of Medical Genetics in TUMS.(Feb 2019-Now)
3. Teaching “Prenatal Screening” to MSC and PhD students of Medical Genetics in TUMS.(Feb 2019-Now)
4. Attending in Masih Daneshvari Hospital Oncology Ward (Jan 2009 - now)
5. Attended in Beauty Skin Care private clinic (Jan 2010-March2013)
6. Teaching “Lung Cancer treatment” to medical students in Masih Daneshvari Hospital Oncology Ward (Feb 2011-Nov 2017)
7. Teaching “Personalized Medicine in Cancer Treatment” to Ph.D students of Molecular Medicine in TUMS.(Jan 2019)
8. Teaching in 3 day Bioinformatic workshop to MSC and Ph.D students of Medical Genetics in TUMS.(Nov 2019)
9. Teaching varieties of subjects in basic Genetics to physiotherapy Senior students in TUMS.(Apr 2019-Jul 2019)

Skills

1. NGS data analysis
2. Protein Homology and Docking investigation using bioinformatic tools
3. Extraction of Cell Free Tumoral DNA
4. Sanger Sequencing Analysis
5. Investigating SNP-effect by Bio-informatics tools
6. Teaching in Personalized Medicine, Basic Genetics and Bioinformatics

Ph.D. Thesis title

Evaluation of Epidermal Growth Factor Receptor mutations and their relation with prognosis of Iranian patients harboring advanced lung adenocarcinoma before treatment with Erlotinib and re-evaluation of these mutations after treatment using Cell Free Tumoral DNA in Masih Daneshvari Hospital 1395-96

- **Thesis final grade:20**